3.14

2.61% +0.08

After Hours: 3.14

NeuroBo Pharmaceuticals Inc (NRBO)

Overview News Price History Discussions Forecast Stock Split

NeuroBo Pharmaceuticals Inc stock is currently priced at $3.14, with a 24-hour trading volume of 16,907. It has seen a +2.61% increased in the last 24 hours and a -26.98% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.08 pivot point. If it approaches the $3.21 resistance level, significant changes may occur.

Previous Close:

$3.06

Open:

$3.06

24h Volume:

16,907

Market Cap:

$14.72M

Revenue:

Net Income/Loss:

$-12.47M

P/E Ratio:

-0.3537

EPS:

-8.877

Net Cash Flow:

$-10.85M

1W Performance:

-6.82%

1M Performance:

-26.98%

6M Performance:

+615.26%

1Y Performance:

+360.48%

1D Range:

$3.00

$3.14

52W Range:

$0.3611

$6.7499

NeuroBo Pharmaceuticals Inc Stock (NRBO) Company Profile

Name

NeuroBo Pharmaceuticals Inc

Sector

Healthcare (1199)

Industry

Biotechnology (688)

Phone

857 702 9600

Address

200 Berkeley Street, Office 19th Floor, Boston, MA

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

NRBO's Discussions on Twitter

NeuroBo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-15-20	Initiated	H.C. Wainwright	Buy

NeuroBo Pharmaceuticals Inc Stock (NRBO) Latest News

Dow Jumps 250 Points; Honeywell Issues Weak Forecast

Benzinga

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations

Benzinga

Nasdaq Surges 100 Points; US Jobless Claims Increase To 224,000

Benzinga

NeuroBo Pharmaceuticals Inc Stock (NRBO) Financials Data

NeuroBo Pharmaceuticals Inc (NRBO) Net Income 2024

NRBO net income (TTM) was -$12.47 million for the quarter ending December 31, 2023, a +10.72% increase year-over-year.

NeuroBo Pharmaceuticals Inc (NRBO) Cash Flow 2024

NRBO recorded a free cash flow (TTM) of -$10.85 million for the quarter ending December 31, 2023, a +7.37% increase year-over-year.

NeuroBo Pharmaceuticals Inc (NRBO) Earnings per Share 2024

NRBO earnings per share (TTM) was -$2.38 for the quarter ending December 31, 2023, a +97.20% growth year-over-year.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.